Literature DB >> 17987363

Susceptibility to chloroquine, mefloquine and artemisinin of Plasmodium vivax in northwestern Thailand.

Birgit Woitsch1, Gunther Wernsdorfer, Kanungnit Congpuong, Chaiporn Rojanawatsirivet, Jeeraphat Sirichaisinthop, Walther H Wernsdorfer.   

Abstract

The in vitro study had the objectives of monitoring the sensitivity of Plasmodium vivax to chloroquine and artemisinin, and to assess its baseline sensitivity to mefloquine in northwestern Thailand in an area near the border to Myanmar. The investigations were carried out in 2004 at the malaria clinics of Mae Sot, Chedi Ko and Mae Ka Sa, all in the district of Mae Sot, Province of Tak. The in vitro tests followed the method of Tasanor. Successful tests were obtained with 45 fresh isolates of P. vivax. The EC(50) and EC(90) values for chloroquine were 120.9 nM and 655.7 nM, respectively, the GMCOC was 1699.7 nM. There was a significant decrease of the chloroquine sensitivity since 1998/1999. However, results of parallel investigations continue to indicate clinical-parasitological sensitivity to chloroquine. With mefloquine the EC(50) and EC(90) the (baseline) values were 131.6 nM and 972.6 nM, respectively, the GMCOC was 1987.0 nM. For artemisinin the EC(50) and EC(90) values were 8.7 nM and 105.2 nM, respectively, the GMCOC was 310.5 nM. As compared to 2002, the sensitivity of P. vivax to artemisinin has shown a slight but not significant increase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17987363     DOI: 10.1007/s00508-007-0872-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  15 in total

1.  Epidemiological basis of malaria control.

Authors:  G MACDONALD
Journal:  Bull World Health Organ       Date:  1956       Impact factor: 9.408

2.  Chloroquine resistance in Plasmodium vivax.

Authors:  P Collignon
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

3.  Plasmodium vivax resistance to chloroquine?

Authors:  K H Rieckmann; D R Davis; D C Hutton
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

Review 4.  Malaria at the turn from the 2nd to the 3rd millenium.

Authors:  Gunther Wernsdorfer; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2003       Impact factor: 1.704

5.  Chloroquine resistant Plasmodium vivax malaria in India.

Authors:  V K Dua; P K Kar; V P Sharma
Journal:  Trop Med Int Health       Date:  1996-12       Impact factor: 2.622

6.  Vivax malaria resistant to treatment and prophylaxis with chloroquine.

Authors:  G S Murphy; H Basri; E M Andersen; M J Bangs; D L Mount; J Gorden; A A Lal; A R Purwokusumo; S Harjosuwarno
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

7.  Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand.

Authors:  Oumaporn Tasanor; Ronnatrai Ruengweerayut; Jeerapat Sirichaisinthop; Kanungnit Congpuong; Walther H Wernsdorfer; Kesara Na-Bangchang
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-02-23       Impact factor: 2.184

8.  Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection.

Authors:  W A Krotoski; W E Collins; R S Bray; P C Garnham; F B Cogswell; R W Gwadz; R Killick-Kendrick; R Wolf; R Sinden; L C Koontz; P S Stanfill
Journal:  Am J Trop Med Hyg       Date:  1982-11       Impact factor: 2.345

9.  Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand.

Authors:  K Congpuong; K Na-Bangchang; K Thimasarn; U Tasanor; W H Wernsdorfer
Journal:  Acta Trop       Date:  2002-08       Impact factor: 3.112

10.  An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine.

Authors:  Oumaporn Tasanor; Harald Noedl; Kesara Na-Bangchang; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Acta Trop       Date:  2002-07       Impact factor: 3.112

View more
  6 in total

1.  Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.

Authors:  Moritz Treiber; Gunther Wernsdorfer; Ursula Wiedermann; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2011-09-22       Impact factor: 1.704

2.  Synergism between pyronaridine and retinol in Plasmodium vivax in vitro.

Authors:  Julia Riedl; Gunther Wernsdorfer; Kanungnit Congpuong; Ursula Wiedermann; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2010-10       Impact factor: 1.704

Review 3.  In vitro drug sensitivity testing in Plasmodium vivax.

Authors:  Walther H Wernsdorfer; Oumaporn Tasanor; Gunther Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial.

Authors:  Yi Poravuth; Duong Socheat; Ronnatrai Rueangweerayut; Chirapong Uthaisin; Aung Pyae Phyo; Neena Valecha; B H Krishnamoorthy Rao; Emiliana Tjitra; Asep Purnama; Isabelle Borghini-Fuhrer; Stephan Duparc; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

5.  Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.

Authors:  Karim Traoré; Seidina A S Diakité; Sekou Bah; Drissa S Konaté; Djeneba Dabitao; Ibrahim Sanogo; Modibo Sangaré; Souleymane Dama; Bourama Keita; Mory Doumbouya; Merepen A Guindo; Seydou Doumbia; Mahamadou Diakité
Journal:  Drugs R D       Date:  2020-09

6.  Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change.

Authors:  Halidou Tinto; Léa N Bonkian; Louis A Nana; Isidore Yerbanga; Moussa Lingani; Adama Kazienga; Innocent Valéa; Hermann Sorgho; Hervé Kpoda; Tinga Robert Guiguemdé; Jean Bosco Ouédraogo; Petronella F Mens; Henk Schallig; Umberto D'Alessandro
Journal:  Malar J       Date:  2014-05-31       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.